Meningococcemia (Meningococcal Infections) - Pipeline Review - H1 2014





Published: March 2014 | Pages: 58 | Format: PDF

 Summary 

 Global Markets Direct’s, ‘Meningococcemia (Meningococcal Infections) - Pipeline Review, H1 2014’, provides an overview of the Meningococcemia (Meningococcal Infections)’s therapeutic pipeline. 

 This report provides comprehensive information on the therapeutic development for Meningococcemia (Meningococcal Infections), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Meningococcemia (Meningococcal Infections) and special features on late-stage and discontinued projects. 

 Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. 

 The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. 

 Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. 

 Scope 

 

  •  The report provides a snapshot of the global therapeutic landscape of Meningococcemia (Meningococcal Infections) 
  •  The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities  
  •  The report reviews key players involved in the therapeutics development for Meningococcemia (Meningococcal Infections) and enlists all their major and minor projects 
  •  The report summarizes all the dormant and discontinued pipeline projects  
  •  A review of the Meningococcemia (Meningococcal Infections) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
  •  Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
  •  A detailed assessment of monotherapy and combination therapy pipeline projects 
  •  Coverage of the Meningococcemia (Meningococcal Infections) pipeline on the basis of target, MoA, route of administration and molecule type 
  •  Latest news and deals relating related to pipeline products 

 

 Reasons to buy 

 

  •  Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies 
  •  Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
  •  Develop strategic initiatives by understanding the focus areas of leading companies 
  •  Identify and understand important and diverse types of therapeutics under development for Meningococcemia (Meningococcal Infections) 
  •  Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline 
  •  Devise corrective measures for pipeline projects by understanding Meningococcemia (Meningococcal Infections) pipeline depth and focus of Indication therapeutics 
  •  Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
  •  Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline 

 

 Introduction 6 

 Global Markets Direct Report Coverage 6 

 Meningococcemia (Meningococcal Infections) Overview 7 

 Therapeutics Development 8 

 Pipeline Products for Meningococcemia (Meningococcal Infections) - Overview 8 

 Pipeline Products for Meningococcemia (Meningococcal Infections) - Comparative Analysis 9 

 Meningococcemia (Meningococcal Infections) - Therapeutics under Development by Companies 10 

 Meningococcemia (Meningococcal Infections) - Therapeutics under Investigation by Universities/Institutes 12 

 Meningococcemia (Meningococcal Infections) - Pipeline Products Glance 13 

 Clinical Stage Products 13 

 Early Stage Products 14 

 Unknown Stage Products 15 

 Meningococcemia (Meningococcal Infections) - Products under Development by Companies 16 

 Meningococcemia (Meningococcal Infections) - Products under Investigation by Universities/Institutes 17 

 Meningococcemia (Meningococcal Infections) - Companies Involved in Therapeutics Development 18 

 GlaxoSmithKline plc 18 

 Biological E. Limited 19 

 Novartis AG 20 

 Panacea Biotec Limited 21 

 Wellstat Vaccines, LLC 22 

 Beijing Minhai Biotechnology Co., Ltd 23 

 Chongqing Zhifei Biological Products Co., Ltd. 24 

 Sanofi Pasteur SA 25 

 Meningococcemia (Meningococcal Infections) - Therapeutics Assessment 26 

 Assessment by Monotherapy Products 26 

 Assessment by Target 27 

 Assessment by Route of Administration 28 

 Assessment by Molecule Type 29 

 Drug Profiles 31 

 Meninge ACYW Conjugate - Drug Profile 31 

 Product Description 31 

 Mechanism of Action 31 

 R&D Progress 31 

 Nimenrix - Drug Profile 32 

 Product Description 32 

 Mechanism of Action 32 

 R&D Progress 32 

 Meningococcal ACW135 Vaccine (Plain) - Drug Profile 35 

 Product Description 35 

 Mechanism of Action 35 

 R&D Progress 35 

 Meningococcal ACYW135 Vaccine (Plain) - Drug Profile 36 

 Product Description 36 

 Mechanism of Action 36 

 R&D Progress 36 

 Meningococcal ACYW135X Vaccine (Plain) - Drug Profile 37 

 Product Description 37 

 Mechanism of Action 37 

 R&D Progress 37 

 MenABCWY Conjugate Vaccine - Drug Profile 38 

 Product Description 38 

 Mechanism of Action 38 

 R&D Progress 38 

 Meningitis Vaccine - Drug Profile 39 

 Product Description 39 

 Mechanism of Action 39 

 R&D Progress 39 

 Meningococcus CY Polysaccharide Conjugate Vaccine - Drug Profile 40 

 Product Description 40 

 Mechanism of Action 40 

 R&D Progress 40 

 Meningococcal B Vaccine - Drug Profile 41 

 Product Description 41 

 Mechanism of Action 41 

 R&D Progress 41 

 ABC Meningococcal Vaccine - Drug Profile 42 

 Product Description 42 

 Mechanism of Action 42 

 R&D Progress 42 

 Meningococcus B Vaccine - Drug Profile 43 

 Product Description 43 

 Mechanism of Action 43 

 R&D Progress 43 

 Meningococcal Vaccine - Drug Profile 44 

 Product Description 44 

 Mechanism of Action 44 

 R&D Progress 44 

 Meningococcal Conjugate Vaccine - Drug Profile 45 

 Product Description 45 

 Mechanism of Action 45 

 R&D Progress 45 

 Meningococcemia (Meningococcal Infections) - Recent Pipeline Updates 46 

 Meningococcemia (Meningococcal Infections) - Dormant Projects 47 

 Meningococcemia (Meningococcal Infections) - Product Development Milestones 48 

 Featured News & Press Releases 48 

 Feb 24, 2014: Novartis provides second US university with Bexsero to help protect students and staff against potentially deadly meningitis B disease 48 

 Dec 09, 2013: Health Canada Approves Bexsero, the First Vaccine Available to Prevent Meningococcal Serogroup B 49 

 Jan 14, 2013: Novartis's Bexsero Shows Potential To Help Provide Broad Protection To Infants Against MenB In Phase III Clinical Trial 50 

 Dec 03, 2012: Sanofi Pasteur Canada Receives Health Canada Approval Of Menactra Meningococcal Conjugate Vaccine Indication For Infants 51 

 Nov 08, 2012: Sanofi Pasteur Announces Publication Of Pivotal Safety And Immunogenicity Data Of Menactra Vaccine For Infants And Toddlers 52 

 Feb 13, 2012: FDA Requests Additional Data On Novartis's Quadrivalent Meningococcal Conjugate Vaccine, Menveo For Expanded Use In Infants And Toddlers 53 

 Jun 16, 2011: FDA Accepts Novartis's Menveo sBLA For Review 53 

 May 12, 2011: Novartis Provides Update On Phase III Study Of Menveo Vaccine To Treat Meningococcal Disease 54 

 Apr 22, 2011: Sanofi Pasteur Announces FDA Approval Of Menactra Meningococcal Conjugate Vaccine Indication for Infants 55 

 Jan 31, 2011: FDA approves the Novartis quadrivalent meningococcal conjugate vaccine, Menveo, for use in children from 2 years of age 56 

 Appendix 57 

 Methodology 57 

 Coverage 57 

 Secondary Research 57 

 Primary Research 57 

 Expert Panel Validation 57 

 Contact Us 58 

 Disclaimer 58 

  

 List of Tables 

 Number of Products under Development for Meningococcemia (Meningococcal Infections), H1 2014 8 

 Number of Products under Development for Meningococcemia (Meningococcal Infections) - Comparative Analysis, H1 2014 9 

 Number of Products under Development by Companies, H1 2014 11 

 Number of Products under Investigation by Universities/Institutes, H1 2014 12 

 Comparative Analysis by Clinical Stage Development, H1 2014 13 

 Comparative Analysis by Early Stage Development, H1 2014 14 

 Comparative Analysis by Unknown Stage Development, H1 2014 15 

 Products under Development by Companies, H1 2014 16 

 Products under Investigation by Universities/Institutes, H1 2014 17 

 Meningococcemia (Meningococcal Infections) - Pipeline by GlaxoSmithKline plc, H1 2014 18 

 Meningococcemia (Meningococcal Infections) - Pipeline by Biological E. Limited, H1 2014 19 

 Meningococcemia (Meningococcal Infections) - Pipeline by Novartis AG, H1 2014 20 

 Meningococcemia (Meningococcal Infections) - Pipeline by Panacea Biotec Limited, H1 2014 21 

 Meningococcemia (Meningococcal Infections) - Pipeline by Wellstat Vaccines, LLC, H1 2014 22 

 Meningococcemia (Meningococcal Infections) - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2014 23 

 Meningococcemia (Meningococcal Infections) - Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H1 2014 24 

 Meningococcemia (Meningococcal Infections) - Pipeline by Sanofi Pasteur SA, H1 2014 25 

 Assessment by Monotherapy Products, H1 2014 26 

 Number of Products by Stage and Target, H1 2014 27 

 Number of Products by Stage and Route of Administration, H1 2014 28 

 Number of Products by Stage and Molecule Type, H1 2014 30 

 Meningococcemia (Meningococcal Infections) Therapeutics - Recent Pipeline Updates, H1 2014 46 

 Meningococcemia (Meningococcal Infections) - Dormant Projects, H1 2014 47 

 

 List of Figures 

 Number of Products under Development for Meningococcemia (Meningococcal Infections), H1 2014 8 

 Number of Products under Development for Meningococcemia (Meningococcal Infections) - Comparative Analysis, H1 2014 9 

 Number of Products under Development by Companies, H1 2014 10 

 Comparative Analysis by Clinical Stage Development, H1 2014 13 

 Comparative Analysis by Early Stage Products, H1 2014 14 

 Assessment by Monotherapy Products, H1 2014 26 

 Number of Products by Top 10 Molecule Type, H1 2014 29 

 Number of Products by Stage and Top 10 Molecule Type, H1 2014 30 

  

 Companies Mentioned 

 GlaxoSmithKline plc 

 Biological E. Limited 

 Novartis AG 

 Panacea Biotec Limited 

 Wellstat Vaccines, LLC 

 Beijing Minhai Biotechnology Co., Ltd 

 Chongqing Zhifei Biological Products Co., Ltd. 

 Sanofi Pasteur SA